See clearly.

Treat optimally.

How can we help you?

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postal Code

By specifying your reason for contact we will be able to provide you with a better service.

We work with partners and distributors who may contact you about this Philips product on our behalf.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Comments

What is cross border data transfer?

I agree on cross-border transfer of personal information.

CEE specific legal checkbox

I would like to receive marketing related electronic communications about Philips products, services, events and promotions that may be relevant to me based on my user preferences and behavior.

Final CEE consent

Angiography alone is

not enough

Angiography provides information on luminal characteristics of peripheral arteries, but severely underestimates the extent of atherosclerosis in patients with PAD, even in “normal appearing” vessels.¹

Visualize the best path forward with IVUS eyes

Philips IVUS provides the visualization needed to gain deeper insights into the lesion and choose the best procedural path forward.

Lumen

Eccentric fibrotic plaque with deep calcium module

Accoustic shadowing

Expand to see critical lesion characteristics

Vessel size

Guides device sizing to ensure precise wall apposition, drug delivery, and placement

Vessel diameter

Lumen diameter

Plaque burden

Plaque morphology

Understand plaque type and severity to help guide proper device selection

Soft

Fibrous

Calcific

Thrombus

CTO

Plaque geometry

Visualize plaque burden location for precise treatment

Concentric

Eccentric

Guidewire position

Confirm true lumen or sub-intimal guidewire location

True lumen

Sub-intimal

Confirm optimal treatment with IVUS

No dissections • Reduce residual stenosis • Stent fully deployed • Treated entire lesion

Get more details on our imaging solutions

Treat optimally with versatility

The Philips portfolio of therapeutic devices offers the versatility needed to treat the majority of PAD cases, including complex lesions.

Crossing

Cross your toughest lesions

Quick-Cross catheter

The support you need to handle any lesion

Pioneer Plus catheter

Only IVUS-guided re-entry catheter

Vessel prep

Prepare multiple lesion morphologies, locations and characteristics

Turbo-Elite and Turbo-Power laser atherectomy

Clinically proven ablation in all lesion types above and below the knee; indicated for ISR²

Phoenix atherectomy system

Front-cutting mechanical atherectomy for treating mixed morphologies with low risk of embolization³

AngioSculpt scoring balloon

Reduces risk of flow limiting dissections including in calcified lesions⁴

Definitive treatment

Treat lesions without leaving metal behind

Stellarex drug-coated balloon

Durable treatment effect in common to complex patients with a low drug dose

2-year primary patency 75.2% in common patients and 72.1% complex patients, including highest rate of severely calcified lesions^5,6

No mortality signal in pooled ILLUMENATE RCT analysis and larger data set through 3 years⁷

Treat safely and effectively

with low-dose Philips Stellarex drug-coated balloon

Learn more

Full view treatment planning

The integration of visualization and interventional technologies allows physicians to see the complete picture and create a more informed and individualized procedural approach.

Explore treatment plan example

Treatment plan example 1

Treatment plan example 2

Treatment plan example 1

Lumen

Eccentric fibrotic plaque with deep calcium nodule

Acoustic shadowing

Treatment plan example 2

Lumen with fresh thrombus

Micro-calcification

Calcified plaque with acoustic shadowing

See clearly

Vessel size: 5.5 mm diameter

Plaque morphology: Fibrotic plaque with intimal and medial calcium

Plaque geometry: Eccentric lesion

Guidewire position: True lumen

Vessel size: 6 mm diameter

Plaque morphology: Mixed, thrombic plaque with medial calcium

Plaque geometry: Eccentric lesion

Guidewire position: True lumen

Treat optimally

Quick-Cross catheter: Confidently cross challenging morphologies

Phoenix deflecting atherectomy: Front facing to cut, capture and clear mixed morphologies, including calcium; deflecting capabilities for larger luminal gain

AngioSculpt scoring balloon: Score calcium to reduce dissection⁴

Stellarex DCB: Designed for performance in calcium

Quick-Cross catheter: Confidently cross challenging morphologies

Turbo-Power laser atherectomy: Forward facing directional debulking to clear thrombus; rotation for improved deliverability in calcified lesions

AngioSculpt scoring balloon: Safely dilate residual stenosis⁴

Stellarex DCB: Designed for performance in calcium

1. Kashyap VS. Pavkov ML, Bishop PD, et al. Angiography underestimates peripheral atherosclerosis: lumenography revisited. J Endovasc Ther. 2008;15(1): 117-125.

2. Dippel et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101

3. Davis, Thomas et al., Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. September 27, 2017, DOI: 10.1177/1708538117712383.

4. Kiesz RS, Scheinert D, Peeters PJ, et al. Results from the international registry of the AngioSculpt Scoring Balloon Catheter. J Am Coll Cardiol. 2008;51:10(suppl B);75.

5. Brodmann M, Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon The ILLUMENATE European Randomized Clinical Trial 2-Year Results, J Am Coll Cardiol Intv 2018;11:2357–64. Dec 2018

6. Mathews J. NCVH, 2019. Stellarex in the Treatment of the SFA and Popliteal: Late-Breaking 3-Year Data. May 29, 2109 New Orleans, LA.

7. Lyden, S. LINC, 2019. Long-term safety data from the Stellarex DCB program Jan. 22, 2019. Leipzig, Germany.

8. Bard Lutonix Instructions for Use, BAW1387400r3

Refer to product labeling for complete indications, contraindications, and warnings.

Caution: federal law restricts this device to sale by or on the order of physician

Some or all products manufactured by Spectranetics, a Philips company. Approved for external distribution. D050123-00 042019

*Data from independent CEC (clinical events committee) adjudication of all events resulting in death across all studies.